

3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

Product Information

TargeTron® Vector pACD4K-C-loxP

Catalog Number **T2826** Storage Temperature –20 °C


TECHNICAL BULLETIN

Product Description

The TargeTron vector, pACD4K-C-loxP, is a 7,745 bp *Escherichia coli* expression vector to be used in conjunction with the TargeTron Gene Knockout System, Catalog Number TA0100. This vector differs from the original pACD4K-C vector in that it has loxP sites flanking each end of the kanamycin ORF. The addition of the loxP sites on this vector allows for multiple site-specific knockouts in the same bacterial chromosome. After an initial "targetron" chromosomal insertion, the kanamycin resistance marker used to select for insertions can be removed via Cre-loxP mediated recombination. After removal of the kanamycin resistance marker, sequential "targetron" insertions can be generated.

Map Features of TargeTron pACD4K-C-loxP vector

| Feature | Map Position |
|----------------------------------|--------------|
| p15A ori | 585-1497 |
| T7 promoter | 1741-1762 |
| 5' exon (IBS) | 1802-1826 |
| Intron RNA | 1827-4182 |
| EBS2 (exon binding sequence 2) | 2049-2053 |
| EBS1d | 2102-2111 |
| 5' loxP site | 2523-2555 |
| Kanamycin-RAM | 2556-3923 |
| td group I intron | 2853-3245 |
| 3' loxP site | 3924-3957 |
| 3' exon | 4183-4192 |
| LtrA ORF | 4429-6228 |
| T1/T2 transcriptional terminator | 6365-6644 |
| Chloramphenicol (Cm) resistance | 7305-219 |



loxP sites that flank the kanamycin-RAM:

5' loxP sequence

5' - CTACTTCGTATAGCATACATTATACGAAGTTAT - 3'

Note: The mutated 5' loxP site shown above was found to be more efficient than the wild-type loxP site in conjunction with targeted group II intron insertions.

3' loxP sequence:

5' - ATAACTTCGTATAGCATACATTATACGAAGTTAT - 3'

Reagent

Supplied at 25 ng/µl in 10 mM Tris-HCl, pH 8.0, with 1 mM EDTA. The provided pACD4K-C-loxP vector is linearized at the *Hind* III and *Bsr*G I sites.

Precautions/Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage

Store at -20 °C. Shipped on wet ice.

Procedures

- A. Removal of kanamycin by Cre-loxP mediated recombination
- After the initial "targetron" insertional knockout has been confirmed, make the knockout strain competent using the RapidTransit™ Transformation Kit, Catalog Number R2653, or an alternative method for making competent cells.
- Obtain a plasmid expressing Cre-recombinase that has a selectable marker other than kanamycin (e.g., chloramphenicol, tetracycline, etc.).
- 3. Transform the knockout strain with the Cre plasmid according to the supplier's recommendations.
- Grow and select for transformants at the appropriate temperature with the appropriate antibiotic.⁴
- Once transformants are obtained, express the Cre recombinase according to supplier recommendations (e.g., shifting temperature from 30 °C to 37 °C for plasmids with thermosensitive promoters).
- 6. Check for removal of kanamycin by replica plating isolated colonies on LB and LB+Kan (25 μg/ml).
- Further verification for removal of kanamycin (~1.0 kb) can be done by colony PCR using gene specific or intron specific primers spanning the kanamycin ORF.
- 8. The PCR amplicon can then be submitted for sequencing. There will be a single loxP scar remaining within the "targetron" once the kanamycin has been removed.

B. Sub-cloning into host specific shuttle vectors

The TargeTron system has previously been adapted to other bacterial hosts by sub-cloning the essential intron components into shuttle/expression vectors. Prior to sub-cloning, the pACD4K-C-loxP vector needs to be circularized. This can be done by running the lacZ control reaction in the TargeTron kit (Product Number TA0100). For adaptation to another host, it is advised to target an easily screenable gene. Sub-cloning the region bound by Hind III and PshA I into an alternative host shuttle vector downstream of a host specific promoter should result in a functional Targetron expression vector. The Hind III-PshA I region should contain the intron RNA and LtrA reverse transcriptase coding regions, as well as the transcriptional terminator. In the final TargeTron shuttle vector, the Hind III and BsrG I sites should be unique since these are used to routinely retarget the intron to knockout specific genes.

C. <u>Delivery of heterologous DNA</u>

The lox-P kanamycin RAM is bound by two Mlu I sites. The loxP-kan-RAM can be removed by Mlu I digestion and replaced with other DNA such as promoters (for mitigating polar effects, if needed), reporter genes, other antibiotic RAM-type markers, etc. The Mlu I site has been used to successfully deliver a trimethoprim–RAM, a kanamycin-RAM (plasmid pACD4K-C in the TA0100 kit and the pACD4K-C-loxP plasmid provided here), and a $lacZ\alpha$ gene. The efficiency of the intron may be affected by insertions at the Mlu I site. A good starting point is to attempt to insert an intron containing heterologous DNA into an easily screenable or selectable gene, such as lacZ.

References:

- Abremski, K. et al., J. Biol. Chem., 261 (1), 391-396 (1986).
- Hartung, M. et al., J. Biol. Chem., 273 (36), 22884-22891 (1998).
- Zhong, J. et al., Nucleic Acids Res., 31 (6), 1656-1664 (2003).
- 4. Buchholz, F. *et al.*, Nucleic Acids Res., **24** (15), 3119-3119 (1996).
- 5. Jones, J.P. et al., Mol. Ther., 11 (5), 687-94 (2005).

RapidTransit is a trademark of Sigma-Aldrich Biotechnology. TargeTron is a registered trademark of InGex , L.L.C.

License Agreement

This product and its use are the subject of one or more of U.S. Patent Nos. 5,698,421, 5,804,418, 6,027,895, and 6,001,608. BEFORE OPENING OR USING THIS PRODUCT, PLEASE READ THE TERMS AND CONDITIONS SET FORTH BELOW. YOUR USE OF THIS PRODUCT SHALL CONSTITUTE ACKNOWLEDGMENT AND ACCEPTANCE OF THESE TERMS AND CONDITIONS. If you do not agree to use this product pursuant to the following terms and conditions, please contact Sigma Technical Services to return the unused and unopened product for a full refund.

The purchase of this product conveys to you, the buyer, the non-transferable right to use the purchased product in non-commercialized research conducted by you. Sigma does not have the right to grant you a license to use this product for any other purposes. If you wish to use this product for any non-research purposes, you must obtain a separate commercial license from InGex LLC. Commercial entities may use this product for research and evaluation purposes for one year from the date of purchase. IF YOU ARE A COMMERCIAL ENTITY, YOUR RIGHT TO USE THIS PRODUCT EXPIRES ONE YEAR FROM THE DATE OF PURCHASE. Any commercial entity that wishes to use this product beyond this one-year period, must obtain a commercial license from InGex, LLC.

You may not transfer the product, its components or any materials or information made through the use of this product, including, but not limited to cell lines, to any third party without prior written approval of Sigma and without the transferee entering into a use license with Sigma. Notwithstanding the foregoing, the product, its components or any materials or information made through use of the product may be transferred by you to your legal affiliates or bona fide third party contractors performing paid work on your behalf provided the use by such third party contractors is limited to performance of work for you and such third party contractors agree to abide by the terms of this license in writing. You may also (a) make such a transfer to a scientific collaborator for research purposes if such collaborator agrees to abide by the usage terms and conditions in writing, (b) disclose in a peer reviewed scientific publication information made through the use of the product and (c) deposit materials made through use of the product as required in association with a peer reviewed scientific publication, provided the recipient is under an obligation not to use or distribute the materials. Your rights and the rights of any third party who obtains the product, its components or any materials or information made through use of the product from you, to use the product will terminate immediately if you or such third party fail to comply with these terms and conditions. You and any third party who obtains the product, its components or any materials or information made

through use of the product from you shall, upon such termination of your rights, destroy all product and components thereof in your control, and notify Sigma of such in writing.

For information on purchasing a license to this product for purposes other than non-commercial research, contact Licensing Department, InGex, LLC, 3655 Vista Ave, St. Louis, MO 63110, 314-865-0113.

Academic and Non-Profit Laboratory Assurance Letter

The T7 system is based on technology developed at Brookhaven National Laboratory under contract with the U.S. Department of Energy and is the subject of U.S. Patent No. 5,693,489 (expiration date, December 2, 2014) assigned to Brookhaven Science Associates, LLC. (BSA). BSA will grant a nonexclusive license for the use of this technology, including the enclosed material, based upon the following assurances:

- 1. These materials are to be used for noncommercial research purposes only. A separate license is required for any commercial use, including use of these materials for research purposes or production purposes by any commercial entity. Information about commercial licenses may be obtained from the Office of Technology Commercialization and Partnerships, Brookhaven National Laboratory, Bldg. 490-C, P.O. Box 5000, Upton, New York 11973-5000, telephone (631)-344-7134.
- 2. No materials that contain the cloned copy of T7 gene 1, the gene for T7 RNA polymerase, may be distributed further to third parties outside of your laboratory, unless the recipient receives a copy of this license and agrees to be bound by its terms. This limitation applies to strains of BL21(DE3), BL21(DE3)pLysS, and BL21(DE3)pLysE, and any derivatives.
- 3. You may refuse this license by returning the enclosed materials unused. By keeping or using the enclosed materials, you agree to be bound to the terms of this license.

AH,PHC 10/10-1